

As the third president and chief executive officer of the HealthCare Institute of New Jersey, Paranicas oversees the trade association for the research-based biopharmaceutical and medical technology industry. HINJ serves as a unified voice for New Jersey’s life sciences industry and seeks to build awareness of this industry’s impact on New Jersey’s quality of life and economic well-being. Before joining HINJ, Paranicas was vice president, corporate secretary and public policy at Becton Dickinson and Co..

Donald Parker, a licensed clinical social worker, is president and chief hospital executive of Hackensack Meridian Health Carrier Clinic, the largest nonprofit behavioral health system in New Jersey, and president of Hackensack Meridian Health Behavioral Health Care Transformation Services/Integrative Medicine. In business for more than a century, Carrier Clinic operates an acute care mental health hospital, a residential treatment center for adolescents, a fully accredited special needs school for students grades 7 through 12, and the Blake Recovery Center, an inpatient unit focused on addiction recovery. As a key opinion leader, Parker can offer unique insights into the 25 percent increase in suicide rates across the country; industry challenges, including the battle against opioid abuse; the latest industry practices; emerging urgent care services in addiction and behavioral health; hospital and mental health center mergers; and behavioral health center redesigns: a new functionality. Before joining Carrier in 2013, Parker served as the vice president for physician services and ambulatory care at St. Joseph’s Health System in Paterson.

As chief innovation officer and vice president of cancer services at Hackensack Meridian Health, Pecora has a lot on his plate. But he is apparently up to the various tasks. HMH credits him with elevating the status of the hospital system’s Theurer Cancer Center to one of the top 50 such institutions in the U.S. On the innovation side, he helped negotiate New Jersey first bundled payment plan for breast cancer patients in commercial insurance plans and oversaw the launch of a mobile app patients can use to update their records and make appointments. Those efforts and others were recognized when Pecora was named as one of the winners in the inaugural NJBIZ Digi-Tech Innovator Awards competition.

Poole is as the 226th president of the Medical Society of New Jersey, having served on the organization’s board of trustees since 2008. Poole is a board-certified general surgeon and fellow of the American College of Surgeons. He practices at North Jersey Surgical Specialists in Hackensack and is a member of Holy Name Medical Partners. As part of the Holy Name family, Poole is serving his second term as president of the Medical Staff at Holy Name Medical Center, after first being elected in 1997. He has previously served as chief of general surgery and director of the Department of Surgery, as well as a member of Holy Name’s board of trustees and Medical Executive Committee. He proactively worked to further expand the New Jersey Healthcare Executives Leadership Academy – a joint initiative to build leadership among physicians and executives from hospitals, post-acute providers and health plan providers, developed collaboratively by MSNJ, the New Jersey Association of Health Plans and the New Jersey Hospital Association and which is currently focusing on alleviating the opioid crisis.

President and chief executive officer of Quest Diagnostics, Rusckowski is a keen conceptual thinker and his experience and knowledge of the issues facing the industry make him the ideal leader to capitalize on the opportunities that lie ahead in a dynamic health care environment. Before Quest, Rusckowski was CEO of Philips Healthcare, the largest unit of Royal Philips Electronics. During his time with Philips, revenues increased from approximately 6 billion euros in 2005 to approximately 9 billion euros in 2011, accounting for approximately 39 percent of Philips consolidated revenues, from 21 percent when he became CEO. Before joining Philips, Rusckowski held numerous management positions with the health care division of Hewlett-Packard/Agilent Technologies. He joined Philips when it acquired Agilent’s Healthcare Solutions Group in 2001.

Sanders, a well-known expert on health care policy and a frequent speaker at national and regional events, leads the state trade association that represents the major health plans in New Jersey, including five Medicaid health plans. Before joining the New Jersey Association of Health Plans in 2006, Sanders served for 15 years in state government positions. He was the executive director of the New Jersey Individual Health Coverage Program Board and the New Jersey Small Employer Health Benefits Program Board, the two state agencies charged with regulating the individual and small group health benefits markets, which then covered about one million New Jersey residents. He began his government service as a deputy attorney general in the Division of Law. As president of the NJAHP, he was appointed by Gov. Jon Corzine to both the Mandated Health Benefits Advisory Commission and the Health Care Access Study Commission.

Anywhere from 500 to 700 medical marijuana patients walk through the doors of Curaleaf every day. The state’s biggest alternative treatment center, located in Bellmawr, has 35 to 40 percent of the sales market of the ever-growing medical marijuana program, which currently numbers 45,800 patients. Schidlovsky recently took a national role at Curaleaf as vice president of Capital Projects, but he spent the last two years as president of Curaleaf NJ during a significant boom in the state’s cannabis industry. Though Curaleaf’s market share might decrease in the coming year as six new ATCs enter the New Jersey market, Schidlovsky isn’t worried about business. “At the pace the market is growing, and the intention of the medical program to expand, I think there’s room for everybody,” he said in a February interview with NJBIZ. Since then, an additional 4,623 patients, 48 doctors and 83 caregivers have joined the program.

Strom is the first chancellor of Rutgers Biomedical and Health Sciences and the executive vice president for Health Affairs at the university. During his five years at Rutgers, Strom has spearheaded the creation of an interprofessional faculty practice group, the Rutgers Health Group; established a formal partnership with RWJBarnabas Health to create New Jersey’s largest and most comprehensive academic health system; and headed a major recruitment drive to bring talented biomedical researchers and clinicians to Rutgers. Before joining the university, Strom was the executive vice dean of institutional affairs, founding chair of the Department of Biostatistics and Epidemiology, founding director of the Center for Clinical Epidemiology and Biostatistics, and founding director of the Graduate Program in Epidemiology and Biostatistics at the Perelman School of Medicine of the University of Pennsylvania. In addition to writing more than 600 papers and 13 books, he has been principal investigator for more than 275 grants, including more than $115 million in direct costs alone.

Taglietti is the resident and chief executive officer of Jersey City-based Scynexis Inc. as well as a member of its board. He previously served as executive vice president for Research and Development and chief medical officer of Forest Laboratories Inc. and as president of the Forest Research Institute until its acquisition by Actavis in 2014. Before joining Forest in 2007, Taglietti held the position of senior vice president, head of global research and development at Stiefel Laboratories Inc., a GSK company, for three years. He joined Stiefel after 12 years at Schering-Plough, where he last held the position of vice president, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. Taglietti currently serves as a director of BioNJ and Delcath Systems Inc. He received his medical degree and board certifications from the University of Pavia in Italy.




